



Ingrezza in India

The CDSCO named-patient coordination pathway — indicative 2026

NEUROLOGY · TARDIVE DYSKINESIA · CHOREA IN HD

The clinical situation

Ingrezza (valbenazine) is an oral selective VMAT2 inhibitor FDA-approved for adults with tardive dyskinesia and for chorea associated with Huntington's disease. Manufactured by Neurocrine Biosciences. Dosing initiates at 40 mg once daily and escalates to 80 mg once daily after one week, with dose adjustments based on tolerability, strong CYP3A4/CYP2D6 interactions, and hepatic function. Pre-treatment workup covers baseline QT assessment, comprehensive metabolic panel, and psychiatric review for depression/suicidality signal per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your neurologist or psychiatrist documents TD or HD-chorea diagnosis, severity scale, prior exposures, and Ingrezza rationale.
- 2 Baseline workup.** QT assessment, LFTs, CYP2D6/3A4 interaction review, psychiatric baseline per FDA labelling.
- 3 CDSCO named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, titration plan, and chain-of-custody commitment.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with controlled-ambient shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases the first 30-day supply; follow-up titration scheduled at week 1.

Indicative economics

Reference US cash-pay range: USD 7,500–9,000 per month of Ingrezza (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete CDSCO application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Neurocrine authorised distribution.

Documentation. Physician kit tailored to CDSCO review, with VMAT2-class QT and CYP interaction annex. **Logistics.**

Controlled-ambient internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through titration and monthly refills. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Ingrezza × India first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/ingrezza-india.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team